Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents

Journal of Invasive Cardiology

Volumn 25, Issue 8, 2013, Pages 383-390

  Yazdani, Saami K ^a   Sheehy, Alexander ^b   Nakano, Masataka ^a   Nakazawa, Gaku ^a   Vorpahl, Marc ^a   Otsuka, Fumiyuki ^a   Donn, Rosy S ^b   Perkins, Laura E ^b   Simonton, Charles A ^b   Kolodgie, Frank D ^a   Virmani, Renu ^a  

^a CVPATH INSTITUTE   (United States)

^b ABBOTT VASCULAR   (United States)

Author keywords

everolimus eluting stent; histopathology; pharmacokinetics; rabbit iliac model; zotarolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; EVEROLIMUS; HEPARIN; POLYMER; ZOTAROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ANTICOAGULANT THERAPY; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BIOCOMPATIBILITY; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; DRUG SAFETY; DRUG SCREENING; FIBRIN DEPOSITION; FOLLOW UP; ILIAC ARTERY STENT; INFLAMMATION; MORPHOMETRICS; NEOINTIMA; NONHUMAN; SCANNING ELECTRON MICROSCOPY; SLOW RELEASE FORMULATION; STENT THROMBOSIS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; ILIAC ARTERY; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; PLAQUE, ATHEROSCLEROTIC; RABBITS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882434636     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773-1780.
2. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193-202.
3. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99(1):44-52.
4. Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention. 2008;4(Suppl C):C7-C10.
5. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004;44(7):1373-1385.
6. Nakazawa G, Finn AV, Ladich E, et al. Drug-eluting stent safety: findings from preclinical studies. Expert Rev Cardiovasc Ther. 2008;6(10):1379-1391.
7. Nakazawa G, Nakano M, Otsuka F, et al. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv. 2011;4(1):38-46.
8. Ribichini F, Joner M, Ferrero V, et al. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol. 2007;50(2):176-185.
9. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52(5):333-342.
10. Schwartz RS, Edelman ER, Carter A, et al; Consensus Committee. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106(14):1867-1873.
11. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J. 2003;24(15):1462-1467.
12. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm. 1988;16(3):303-309.
13. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136-146.
14. Verheye S, Martinet W, Kockx MM, et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 2007;49(6):706-715.
15. Zahedmanesh H, Lally C. Determination of the influence of stent strut thickness using the finite element method: implications for vascular injury and in-stent restenosis. Med Biol Eng Comput. 2009;47(4):385-393.
16. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115(18):2435-2441.
17. Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (abt-578) eluting stents. Adv Drug Deliv Rev. 2006;58(3):437-446.